Program
Aspirin
Also written as “dabigatran with ASA”, “ASA” and “Acetylsalicylic acid (Aspirin, BAY1019036)”.
Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Common Cold · Thrombosis · Peptic Ulcer, led by 28 companies.
Drug pageAspirin: every studyMany companies study it; this page follows only the 70 they lead. All 675 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 211 open or running | phase 4since Dec 15, 2009 | Jul 12, 2007 | Mar 10, 2027phase 1 · NCT07652723 |
| Boehringer Ingelheimits history only | 60 open or running | phase 4since Aug 10, 2005 | Aug 10, 2005 | none ahead |
| Bristol-Myers Squibb | 50 open or running | phase 1since Jul 8, 2009 | Jul 8, 2009 | none ahead |
| Abbottits history only | 30 open or running | phase 3since Feb 21, 2008 | Feb 21, 2008 | none ahead |
| Boston Scientificits history only | 30 open or running | phase 4since May 1, 2012 | Dec 21, 2011 | none ahead |
| Johnson & Johnsonits history only | 30 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Aralez Pharmaceuticalsits history only | 20 open or running | phase 1since Feb 27, 2007 | Feb 27, 2007 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 4since May 26, 2016 | Aug 1, 2011 | none ahead |
| Biogenits history only | 20 open or running | phase 4since Mar 14, 2014 | Jan 20, 2011 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 20 open or running | phase 1since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since May 2, 2013 | May 2, 2013 | none ahead |
| Merckits history only | 20 open or running | phase 1since Nov 10, 2009 | Nov 10, 2009 | none ahead |
| PLx Pharmaits history only | 20 open or running | phase 2since Mar 10, 2009 | Mar 10, 2009 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 3since Nov 12, 2009 | Nov 12, 2009 | none ahead |
| CeloNova BioSciencesits history only | 10 open or running | no phasesince Aug 19, 2014 | Aug 19, 2014 | none ahead |
| Cordisits history only | 10 open or running | phase 4since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Egymedicalpediaits history only | 11 open or running | no phasesince Feb 7, 2024 | Feb 7, 2024 | none ahead |
| Fertility Center of Las Vegasits history only | 11 open or running | phase 4since Nov 10, 2023 | Nov 10, 2023 | none ahead |
| GC Biopharmaits history only | 10 open or running | phase 4since May 16, 2019 | May 16, 2019 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 4since Mar 23, 2020 | Mar 23, 2020 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| New Haven Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Otsukaits history only | 10 open or running | phase 1since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Regeneron Pharmaceuticalsits history only | 10 open or running | no phasesince Sep 15, 2022 | Sep 15, 2022 | none ahead |
| Rhoshan Pharmaceuticalsits history only | 10 open or running | phase 1since Dec 18, 2025 | Dec 18, 2025 | none ahead |
| Vecturaits history only | 10 open or running | phase 1since Nov 1, 2022 | Nov 1, 2022 | none ahead |
| Vita Green Health Productsits history only | 10 open or running | phase 1since Mar 4, 2021 | Mar 4, 2021 | none ahead |
Also a collaborator on its studies: Cardialysis, Terumo and ClinLogix.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2009First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT00935506 · 15 enrolled · United States
- Jan 14, 2015Phase 1 study in ThrombosisNCT02341638 · 148 enrolled · United States
- Apr 2, 2015Phase 1 study in ThrombosisNCT02439190 · 42 enrolled · United Kingdom
- Jun 21, 2017Phase 1 study in ThrombosisNCT03197779 · 691 enrolled · United States
- Oct 4, 2018Phase 1 study in Healthy VolunteersNCT03698513 · 113 enrolled · United States
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 5 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Feb 19, 2019 | 113 |
| NCT03197779Thrombosis · United States | 1 | Completed | Feb 2, 2016 | 691 |
| NCT02439190Thrombosis · United Kingdom | 1 | Completed | Mar 2016 | 42 |
| NCT02341638Thrombosis · United States | 1 | Completed | Sep 2015 | 148 |
| NCT00935506Cardiovascular Diseases · United States | 1 | Completed | Oct 2009 | 15 |
How it is read
Names in the registry
- “Aspirin”, 25 entries
- “dabigatran with ASA”, 6 entries
- “ASA”, 5 entries
- “Acetylsalicylic acid (Aspirin, BAY1019036)”, 5 entries
- “Acetylsalicylic acid (Aspirin, BAYE4465)”, 5 entries
Codes read as this program: BAY1019036.
Conditions, from the studies’ own filings
- Coronary Artery Disease, 9 studies
- Cardiovascular Diseases, 5 studies
- Common Cold, 5 studies
- Thrombosis, 4 studies
- Peptic Ulcer, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.